戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  glucuronic acid, any-N-acetylated sugar, or ribitol).
2 lpNAc-(1-->5)-Rbo-1-P-->, respectively (Rbo, ribitol).
3 bitol, whereas SLC35A4 might only accept CDP-ribitol.
4  Both serotypes have a beta-d-Galp branch to Ribitol.
5 acetamido-2-deoxy-beta-glucopyranosyl)-1-->4-ribitol-1-OPO3-->.
6 terin-6-ylmethyl-l-(4-aminophenyl)-1-deoxy-D-ribitol 5'-phosphate (4') in a reaction stimulated by th
7 terin-6-ylmethyl-1-(4-aminophenyl)-1-deoxy-D-ribitol (5').
8 ose (1-->3) glucose (1-->3) rhamnose (1-->3) ribitol (5-->phosphate.
9 1 (1-->3) glucose 2 (1-->3) rhamnose (1-->3) ribitol (5-->phosphate.
10 indings identify linkages from alpha-Galp to ribitol-5-phosphate and from this residue to adjacent Ga
11 accharide capsule is a polymer of ribose and ribitol-5-phosphate and is a critical determinant of vir
12 lpha1-2 transfer of Gal pyranoside (Galp) to ribitol-5-phosphate in the synthesis of CPS10A, CPS47F,
13 d CPS34 but with alpha1-1 transfer of Gal to ribitol-5-phosphate in the synthesis of CPS39.
14                            FKRP functions as ribitol-5-phosphate transferase with CDP-ribitol as the
15            It has been proposed that FKRP, a ribitol-5-phosphate transferase, is a participant in alp
16 levels of CDP-ribitol, the substrate for the ribitol-5-phosphate transferases FKRP and FKTN.
17 ical, except for the linkage between Gal and ribitol-5-phosphate, which is alpha1-2 in strain SK144 v
18 s identify genetic markers for the different ribitol-5-phosphate-containing types of RPS present in S
19 associated with alpha1-1 transfer of Galp to ribitol-5-phosphate.
20 -dependent alpha1-4 linkages between Gal and ribitol-5-phosphate.
21 -5-[1-alpha -D- ribofuranosyl 5-phosphate]-D-ribitol (9').
22  iminosugars including 1,5-dideoxy-1,5-imino-ribitol and 1,5-dideoxy-1,5-imino-DL-arabinitol, startin
23 f other bacterial polysaccharides containing ribitol and glycerol phosphates, including H. influenzae
24  One group was negative for I-erythritol and ribitol and included all the isolates belonging to Nocar
25 ir similarity in enhancing the levels of CDP-ribitol and matriglycan synthesis.
26 ng: whereas the isoalloxazine ring linked to ribitol and one phosphate is sufficient to drive complet
27                    Clinical trials with both ribitol and ribose have been reported for treating LGMD2
28                                Supplement of ribitol and ribose have been reported to increase the le
29  D-glucitol, i-myo-inositol, D-mannitol, and ribitol and susceptibility to amoxicillin-clavulanic aci
30 ee groups were positive for I-erythritol and ribitol and were grouped within Nocardia transvalensis.
31 d urinary excretion of erythritol, arabitol, ribitol, and pent(ul)ose-5-phosphates was detected, as w
32 a polyhydroxy alkane, including glycerol and ribitol, and phosphoric acid, joined to form phosphodies
33 butyric acid (DHBA), 3,4-DHBA, ribonic acid, ribitol, and the triglycerides 50:1 and 50:2 significant
34 precursor to the 1-(4-aminophenyl)-1-deoxy-D-ribitol (APDR) moiety present in the C(1) carrier coenzy
35 col (SG or UG) in residues such as glycerol, ribitol, arabinitol, furanosyl galactose, and sialic aci
36 s [(1S)-substituted 1, 4-dideoxy-1,4-imino-D-ribitols] are powerful inhibitors for the nonspecific nu
37  as ribitol-5-phosphate transferase with CDP-ribitol as the substrate for the extension of the glycan
38 (9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol at the depurination site binds four times better
39 r RNA stem-loop with 1,4-dideoxy-1,4-imino-D-ribitol at the depurination site binds with a K(d) of 1.
40 very of WWS myotubes is promoted not only by ribitol but also by its precursor ribose.
41                                Supplement of ribitol changes lysophospholipid sub-pathway metabolite
42                       Disparity in GlcNAc to ribitol connectivity, as well as variable O-acetylation
43                We recently demonstrated that ribitol, considered to be a metabolic end-product, enhan
44 current study, we tested the hypothesis that ribitol could also enhance matriglycan expression in can
45 nt pyridine nucleotide reductase and glucose/ribitol dehydrogenase families, respectively.
46                                          The ribitol effect is associated with an increase in levels
47 ylose, mannose, maltose, gluconolactone, and ribitol) exclusively used by soil commensal bacteria (no
48 o 7,8-didemethyl-8-hydroxy-5-deazariboflavin ribitol (Fo).
49 , ribose, lyxose, lyxitol (0.5 mo); mannose, ribitol, glycerol, isothreonic acid, lyxitol (2 mo); lyx
50 9-deazaguanin-9-yl)-1,4-dideoxy-1, 4-imino-D-ribitol (immucillin-G).
51 azahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol (immucillin-H) and (1S)-1-(9-deazaguanin-9-yl)-1
52 educed sugar nucleotide for the insertion of ribitol in a phosphodiester linkage to the glycoprotein.
53         Thus, we propose a novel structure-a ribitol in a phosphodiester linkage-for the moiety on wh
54  been reported to increase the levels of CDP-ribitol in both cells and in muscles in vivo.
55 ngs provide the rationale for testing ribose/ribitol in combination with NAD+ to treat WWS and other
56 levated amounts of erythritol, arabitol, and ribitol in the plasma of affected individuals.
57                                The fact that ribitol is a metabolite in nature and has already been t
58   Our results showed for the first time that ribitol is able to significantly enhance the expression
59                            Direct use of CDP-ribitol is also effective for matriglycan expression.
60                                    Since CDP-ribitol is synthesized in the cytoplasm, we hypothesized
61 azahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol] is a 23 pM inhibitor of bovine purine nucleosid
62  cells, FGGY can additionally participate in ribitol metabolism.
63 or with a protonated 1,4-dideoxy-1,4-imino-D-ribitol moiety, a 4-azasugar mimic, at the depurination
64 good overall yields of 1,5-dideoxy-1,5-imino-ribitol of 54%, 1,5-dideoxy-1,5-imino-D-arabinitol of 48
65 onal modeling demonstrate that Galf(OAc)-1,1-Ribitol of the repeating unit of 35B CPS constitutes the
66 glycosyltransferase that in vivo transfers a ribitol phosphate group from a CDP -ribitol present in m
67 s the only mammalian glycan known to contain ribitol phosphate groups.
68 lgi apparatus use CDP-ribitol to incorporate ribitol phosphate into the glycan chain of a-dystroglyca
69 eaves WTA synthesis intermediates, releasing ribitol phosphate into the medium and recycling bactopre
70 d polymers containing repeating polyglycerol/ribitol phosphate moieties.
71 , catalyzes both the addition of the priming ribitol phosphate onto the linkage unit and the subseque
72 Complementation studies show that a putative ribitol phosphate polymerase, TarL, catalyzes both the a
73 Deltalcp mutant synthesized WTA yet released ribitol phosphate polymers into the extracellular medium
74 so a bifunctional enzyme that catalyzes both ribitol phosphate priming and polymerization.
75               Two major structures, 1,5-poly(ribitol phosphate) and 1,3-poly(glycerol phosphate), wit
76 ria toxin and the attachment of poly(ribosyl-ribitol phosphate) carbohydrate chains results in a stil
77  revised assembly pathway for the late-stage ribitol phosphate-utilizing enzymes is proposed.
78 ib capsular polysaccharide IgG, poly-ribosyl-ribitol-phosphate (PRP), IgG subclass, and cellular immu
79 , the form of IgA in response to polyribosyl-ribitol-phosphate (PRP), the capsular polysaccharide of
80 nd tetrasaccharides and a negatively charged ribitol-phosphate construct to BSA.
81 stor of BL21(DE3) may have produced a ribose/ribitol-phosphate containing polysaccharide.
82 cetylmuramic acid with wall teichoic acid, a ribitol-phosphate polymer tethered to murein linkage uni
83 ws: 24F has arabinitol-phosphate and 24B has ribitol-phosphate.
84 ion of proteins in cells but still supported ribitol phosphorylation.
85         Lipoteichoic acid (LTA), a cell wall ribitol polymer from Gram-positive organisms, mediates i
86 nsfers a ribitol phosphate group from a CDP -ribitol present in muscles to alpha-DG, while in vitro i
87                It is known that the putative ribitol primase, TarK, is also a bifunctional enzyme tha
88                                              Ribitol relies on residual FKRP function and restores li
89 or-sera 24d and 24e recognize arabinitol and ribitol, respectively, which explains the serology of se
90                                ISPD is a CDP-ribitol (ribose) pyrophosphorylase that generates the re
91 ow dose (1e-13 vg/kg) AAV-FKRP combined with ribitol showed a 22.6% increase in positive matriglycan
92      This functional glycan contains a novel ribitol structure that links a phosphotrisaccharide to x
93                                              Ribitol teichoic acid (RTA) (1 microg/ml) induced a twof
94 ut not by dextran, dextran sulfate, heparin, ribitol teichoic acid, or soluble low molecular weight P
95 associated with an increase in levels of CDP-ribitol, the substrate for the ribitol-5-phosphate trans
96 F and 24B repeating units, with the ratio of ribitol to arabinitol being strain dependent.
97       Enzymes in the Golgi apparatus use CDP-ribitol to incorporate ribitol phosphate into the glycan
98                       We discovered that CDP-ribitol transport relies on the CMP-sialic acid transpor
99 lite profiles of the skeletal muscle between ribitol-treated and ribose-treated FKRP mutant mice.
100 deno-associated virus (AAV) gene therapy and ribitol treatment demonstrating significant therapeutic
101                                              Ribitol treatment does not alter the expression of FKRP,
102 n with highest levels in S and G2 phases and ribitol treatment does not alter the pattern.
103  cells, ribulose could only be detected when ribitol was added to the cultivation medium, and under t
104 ich is capable of transferring arabinitol or ribitol when arabinitol is limiting.
105 ion of high-dose (5e-13 vg/kg) AAV-FKRP with ribitol, whereas low dose (1e-13 vg/kg) AAV-FKRP combine
106 he bulky CMP-sialic acid and the smaller CDP-ribitol, whereas SLC35A4 might only accept CDP-ribitol.
107  support the potential benefits of combining ribitol with AAV gene therapy for treating FKRP-related
108   After all, from studying such pentitols as ribitol with Professor Touster at Vanderbilt University
109 h of which starts with glucose and ends with ribitol, with the lipid anchor predicted to be Glc(beta1

 
Page Top